{"id":66579,"date":"2026-05-28T21:07:08","date_gmt":"2026-05-28T13:07:08","guid":{"rendered":"https:\/\/flcube.com\/?p=66579"},"modified":"2026-05-28T21:07:10","modified_gmt":"2026-05-28T13:07:10","slug":"shanghai-pharma-and-trinomab-partner-to-commercialize-xintituo-in-philippines-worlds-first-recombinant-anti-tetanus-toxin-monoclonal-antibody-expands-overseas","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66579","title":{"rendered":"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World&#8217;s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Pharmaceutical Holding Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2607:HKG\">HKG: 2607<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/601607:SHA\">SHA: 601607<\/a>) has announced a strategic partnership with <strong>Zhuhai Trinomab Biopharmaceutical Co., Ltd.<\/strong> to jointly commercialize <strong>Xintituo (siltartoxatug)<\/strong> in the Philippines. The collaboration marks a significant step in expanding access to the world&#8217;s first recombinant anti-tetanus toxin monoclonal antibody (mAb) beyond China, where it received approval last year.<\/p>\n\n\n\n<h2 id=\"h-partnership-framework\" class=\"wp-block-heading\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Shanghai Pharmaceutical Holding Co., Ltd. &amp; Zhuhai Trinomab Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Xintituo (siltartoxatug) \u2013 recombinant anti-tetanus toxin monoclonal antibody<\/td><\/tr><tr><td><strong>Market<\/strong><\/td><td>Philippines<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Approved in China (2025)<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>World&#8217;s first recombinant anti-tetanus toxin mAb independently developed by Trinomab<\/td><\/tr><tr><td><strong>Commercial Strategy<\/strong><\/td><td>Joint registration and commercialization leveraging complementary capabilities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-clinical-significance\" class=\"wp-block-heading\">Product Profile &amp; Clinical Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Recombinant anti-tetanus toxin monoclonal antibody (mAb)<\/li>\n\n\n\n<li><strong>Brand Name:<\/strong> Xintituo (siltartoxatug)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class therapy offering targeted neutralization of tetanus toxin<\/li>\n\n\n\n<li><strong>Development:<\/strong> Independently developed by Zhuhai Trinomab Biopharmaceutical<\/li>\n\n\n\n<li><strong>Approval Status:<\/strong> Approved in China in 2025<\/li>\n\n\n\n<li><strong>Therapeutic Value:<\/strong> Provides modern, high-quality alternative to traditional tetanus treatments<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Capability<\/th><th>Shanghai Pharma Contribution<\/th><th>Trinomab Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D<\/strong><\/td><td>Regulatory expertise for international markets<\/td><td>Innovative drug development<\/td><\/tr><tr><td><strong>Manufacturing<\/strong><\/td><td>Quality assurance systems compliant with international standards<\/td><td>Proprietary production technology<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>Established overseas distribution networks<\/td><td>Product-specific regulatory documentation<\/td><\/tr><tr><td><strong>Commercial Operations<\/strong><\/td><td>Local market expertise in Southeast Asia<\/td><td>Clinical data and product knowledge<\/td><\/tr><tr><td><strong>Value Proposition<\/strong><\/td><td>Accelerated market entry through existing infrastructure<\/td><td>Cutting-edge therapeutic addressing unmet needs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The partnership aims to address critical gaps in tetanus treatment options in the Philippines by combining Shanghai Pharma&#8217;s extensive experience in international pharmaceutical commercialization with Trinomab&#8217;s innovative biologics platform. This collaboration represents a strategic move by both Chinese companies to expand their global footprint in the biopharmaceutical sector.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Philippines Healthcare Landscape:<\/strong> High burden of tetanus cases with limited access to modern treatments<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Xintituo offers superior specificity and safety profile compared to traditional antitoxins<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Significant market opportunity in Southeast Asia and potential gateway to broader ASEAN markets<\/li>\n\n\n\n<li><strong>Strategic Alignment:<\/strong> Supports China&#8217;s &#8220;Going Global&#8221; initiative for domestic biopharmaceutical innovation<\/li>\n\n\n\n<li><strong>Future Expansion:<\/strong> Success in Philippines could pave way for registration in other emerging markets with high tetanus burden<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the partnership between Shanghai Pharmaceutical and Trinomab, including regulatory timelines and commercial expectations for Xintituo in the Philippines. Actual results may differ due to risks including regulatory approvals, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66580,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[890,891,196,1848],"class_list":["post-66579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-2607","tag-sha-601607","tag-shanghai-pharmaceuticals","tag-trinomab-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World&#039;s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with Zhuhai Trinomab Biopharmaceutical Co., Ltd. to jointly commercialize Xintituo (siltartoxatug) in the Philippines. The collaboration marks a significant step in expanding access to the world&#039;s first recombinant anti-tetanus toxin monoclonal antibody (mAb) beyond China, where it received approval last year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66579\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World&#039;s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas\" \/>\n<meta property=\"og:description\" content=\"Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with Zhuhai Trinomab Biopharmaceutical Co., Ltd. to jointly commercialize Xintituo (siltartoxatug) in the Philippines. The collaboration marks a significant step in expanding access to the world&#039;s first recombinant anti-tetanus toxin monoclonal antibody (mAb) beyond China, where it received approval last year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66579\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T13:07:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T13:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World&#8217;s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas\",\"datePublished\":\"2026-05-28T13:07:08+00:00\",\"dateModified\":\"2026-05-28T13:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579\"},\"wordCount\":410,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2802.webp\",\"keywords\":[\"HKG: 2607\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\",\"Trinomab Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66579#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66579\",\"name\":\"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World's First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2802.webp\",\"datePublished\":\"2026-05-28T13:07:08+00:00\",\"dateModified\":\"2026-05-28T13:07:10+00:00\",\"description\":\"Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with Zhuhai Trinomab Biopharmaceutical Co., Ltd. to jointly commercialize Xintituo (siltartoxatug) in the Philippines. The collaboration marks a significant step in expanding access to the world's first recombinant anti-tetanus toxin monoclonal antibody (mAb) beyond China, where it received approval last year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66579\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World's First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66579#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World&#8217;s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World's First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with Zhuhai Trinomab Biopharmaceutical Co., Ltd. to jointly commercialize Xintituo (siltartoxatug) in the Philippines. The collaboration marks a significant step in expanding access to the world's first recombinant anti-tetanus toxin monoclonal antibody (mAb) beyond China, where it received approval last year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66579","og_locale":"en_US","og_type":"article","og_title":"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World's First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas","og_description":"Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with Zhuhai Trinomab Biopharmaceutical Co., Ltd. to jointly commercialize Xintituo (siltartoxatug) in the Philippines. The collaboration marks a significant step in expanding access to the world's first recombinant anti-tetanus toxin monoclonal antibody (mAb) beyond China, where it received approval last year.","og_url":"https:\/\/flcube.com\/?p=66579","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-28T13:07:08+00:00","article_modified_time":"2026-05-28T13:07:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66579#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66579"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World&#8217;s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas","datePublished":"2026-05-28T13:07:08+00:00","dateModified":"2026-05-28T13:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66579"},"wordCount":410,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66579#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2802.webp","keywords":["HKG: 2607","SHA: 601607","Shanghai Pharmaceuticals","Trinomab Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66579#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66579","url":"https:\/\/flcube.com\/?p=66579","name":"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World's First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66579#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66579#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2802.webp","datePublished":"2026-05-28T13:07:08+00:00","dateModified":"2026-05-28T13:07:10+00:00","description":"Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with Zhuhai Trinomab Biopharmaceutical Co., Ltd. to jointly commercialize Xintituo (siltartoxatug) in the Philippines. The collaboration marks a significant step in expanding access to the world's first recombinant anti-tetanus toxin monoclonal antibody (mAb) beyond China, where it received approval last year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66579#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66579"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66579#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2802.webp","width":1080,"height":608,"caption":"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World's First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66579#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines \u2013 World&#8217;s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66579"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66579\/revisions"}],"predecessor-version":[{"id":66581,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66579\/revisions\/66581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66580"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}